GSK-2849466
Overview of the experimental drug GSK-2849466
GSK-2849466[edit]
GSK-2849466 is an experimental drug developed by GlaxoSmithKline (GSK) that acts as a potent and selective inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP). This compound is part of a class of drugs known as PARP inhibitors, which are being investigated for their potential use in the treatment of various types of cancer.
Mechanism of Action[edit]
GSK-2849466 functions by inhibiting the activity of PARP enzymes, which play a crucial role in the repair of DNA single-strand breaks through the base excision repair pathway. By blocking PARP activity, GSK-2849466 prevents the repair of DNA damage in cancer cells, leading to the accumulation of DNA breaks and ultimately causing cell death. This mechanism is particularly effective in cancer cells that are already deficient in other DNA repair pathways, such as those with BRCA1 or BRCA2 mutations.
Clinical Development[edit]
GSK-2849466 is currently undergoing clinical trials to evaluate its safety and efficacy in patients with various types of cancer, including breast cancer, ovarian cancer, and prostate cancer. The drug is being tested both as a monotherapy and in combination with other anticancer agents to determine its potential benefits in different therapeutic contexts.
Potential Benefits[edit]
The use of GSK-2849466 as a PARP inhibitor offers several potential benefits in cancer treatment. By specifically targeting cancer cells with defective DNA repair mechanisms, it may provide a more targeted approach to therapy, reducing damage to normal cells and minimizing side effects. Additionally, the combination of GSK-2849466 with other treatments may enhance the overall effectiveness of cancer therapy.
Challenges and Considerations[edit]
While GSK-2849466 shows promise, there are challenges associated with its development and use. These include the need to identify patients who are most likely to benefit from PARP inhibition, managing potential resistance mechanisms that cancer cells may develop, and addressing any adverse effects that may arise during treatment.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
